IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model

Journal of Molecular Medicine

Volumn 90, Issue 2, 2012, Pages 139-147

  Schilling, Bastian ^a,b   Harasymczuk, Malgorzata ^a,b   Schuler, Patrick ^a,b   Egan, James E ^c   Whiteside, Theresa L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c IRX Therapeutics Inc   (United States)

Author keywords

Cancer immunotherapy; Cytokines; Immunomodulator; IRX 2; T helper cells; Teff; Treg; Tumor microenvironment

Indexed keywords

CYTOKINE IRX 2; IMMUNOMODULATING AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PHENOTYPE; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; WESTERN BLOTTING;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOKINES; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84857370520     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-011-0813-8     Document Type: Article

References (32)

1. Wolf GT, Fee WE, Jr., Dolan RW, Moyer JS, Kaplan MJ, Spring PM, Suen J, Kenady DE, Newman JG, Carroll WR et al. (2011) Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck. doi: 10.1002/hed.21660
2. SM Freeman JL Franco DE Kenady L Baltzer Z Roth HJ Brandwein JW Hadden 2011 A phase 1 safety study of an irx-2 regimen in patients with squamous cell carcinoma of the head and neck Am J Clin Oncol 34 2 173 178 10.1097/COC. 0b013e3181dbb9d8 20539208 1:CAS:528:DC%2BC3MXlslWhsr4%3D
3. JW Hadden E Verastegui E Hadden 2007 IRX-2 and thymosin alpha1 (Zadaxin) increase T lymphocytes in T lymphocytopenic mice and humans Ann N Y Acad Sci 1112 245 255 10.1196/annals.1415.032 17600288 10.1196/annals.1415.032 1:CAS:528:DC%2BD2sXhtlWntrnI
4. A Meneses E Verastegui JL Barrera J de la Garza JW Hadden 2003 Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2 Int Immunopharmacol 3 1083 1091 10.1016/S1567-5769(03)00017-1 12860165 10.1016/S1567-5769(03)00017-1 1:CAS:528:DC%2BD3sXlt1altbg%3D
5. J Hadden E Verastegui JL Barrera M Kurman A Meneses JW Zinser J de la Garza E Hadden 2003 A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck Int Immunopharmacol 3 1073 1081 10.1016/S1567-5769(03) 00029-8 12860164 10.1016/S1567-5769(03)00029-8 1:CAS:528:DC%2BD3sXlt1altbs%3D
6. JE Egan KJ Quadrini F Santiago-Schwarz JW Hadden HJ Brandwein KL Signorelli 2007 IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro J Immunother 30 624 633 10.1097/CJI.0b013e3180691593 17667526 10.1097/CJI.0b013e3180691593 1:CAS:528:DC%2BD2sXotlKht7o%3D
7. M Czystowska J Han MJ Szczepanski M Szajnik K Quadrini H Brandwein JW Hadden K Signorelli TL Whiteside 2009 IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death Cell Death Differ 16 708 718 10.1038/cdd.2008.197 19180118 10.1038/cdd.2008.197 1:CAS:528: DC%2BD1MXks1ygsbw%3D
8. TL Whiteside 2008 The tumor microenvironment and its role in promoting tumor growth Oncogene 27 5904 5912 10.1038/onc.2008.271 18836471 10.1038/onc.2008.271 1:CAS:528:DC%2BD1cXhtF2msbbK
9. C Bergmann L Strauss R Zeidler S Lang TL Whiteside 2007 Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment Cancer Immunol Immunother 56 1429 1442 10.1007/s00262-007-0280-9 17265021 10.1007/s00262-007-0280-9
10. DS Heo C Snyderman SM Gollin S Pan E Walker R Deka EL Barnes JT Johnson RB Herberman TL Whiteside 1989 Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines Cancer Res 49 5167 5175 2766286 1:STN:280:DyaL1MzlsVaqtw%3D%3D
11. C Bergmann L Strauss R Zeidler S Lang TL Whiteside 2007 Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma Cancer Res 67 8865 8873 10.1158/0008-5472.CAN-07-0767 17875728 10.1158/0008-5472.CAN-07-0767 1:CAS:528:DC%2BD2sXhtVCit7jF
12. J Zhou WE Paul 2009 Heterogeneity and plasticity of T helper cells Cell Res 20 4 12 10.1038/cr.2009.138 10.1038/cr.2009.138
13. M Ahmadzadeh SA Rosenberg 2006 IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients Blood 107 2409 2414 10.1182/blood-2005-06-2399 16304057 10.1182/blood-2005-06-2399 1:CAS:528:DC%2BD28XisFOjtbY%3D
14. + T cells in the circulation of patients with squamous cell carcinoma of the head and neck Clin Cancer Res 13 6301 6311 10.1158/1078-0432.CCR-07-1403 17975141 10.1158/1078-0432.CCR-07-1403 1:CAS:528:DC%2BD2sXht1Cgtb%2FM
15. C Bergmann L Strauss Y Wang MJ Szczepanski S Lang JT Johnson TL Whiteside 2008 T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease Clin Cancer Res 14 3706 3715 10.1158/1078-0432.CCR-07-5126 18559587 10.1158/1078-0432.CCR-07-5126 1:CAS:528:DC%2BD1cXntlWrsr0%3D
16. O Alhamarneh F Agada L Madden N Stafford J Greenman 2011 Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma Head Neck 33 415 423 10.1002/hed.21464 20645289
17. FA Sinicrope RL Rego SM Ansell KL Knutson NR Foster DJ Sargent 2009 Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma Gastroenterology 137 1270 1279 10.1053/j.gastro.2009.06.053 19577568 10.1053/j.gastro.2009.06.053 1:CAS:528:DC%2BD1MXht12gtr%2FP
18. P Salama M Phillips F Grieu M Morris N Zeps D Joseph C Platell B Iacopetta 2009 Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer J Clin Oncol 27 186 192 10.1200/JCO.2008.18.7229 19064967 10.1200/JCO.2008.18.7229
19. F Liotta M Gacci F Frosali V Querci G Vittori A Lapini V Santarlasci S Serni L Cosmi L Maggi, et al. 2011 Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma BJU Int 107 9 1500 1506 10.1111/j.1464-410X.2010.09555.x 20735382 10.1111/j.1464-410X.2010.09555.x 1:CAS:528:DC%2BC3MXns1Churo%3D
20. K Shimizu M Nakata Y Hirami T Yukawa A Maeda K Tanemoto 2010 Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer J Thorac Oncol 5 585 590 10.1097/JTO.0b013e3181d60fd7 20234320
21. C Badoual S Hans J Rodriguez S Peyrard C Klein H Agueznay Nel V Mosseri O Laccourreye P Bruneval WH Fridman, et al. 2006 Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers Clin Cancer Res 12 465 472 10.1158/1078-0432.CCR-05-1886 16428488 10.1158/1078-0432.CCR-05-1886 1:CAS:528:DC%2BD28XmtlKitg%3D%3D
22. L Strauss TL Whiteside A Knights C Bergmann A Knuth A Zippelius 2007 Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin J Immunol 178 320 329 17182569 1:CAS:528:DC%2BD2sXnvVWn
23. R Zeiser DB Leveson-Gower EA Zambricki N Kambham A Beilhack J Loh JZ Hou RS Negrin 2008 Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells Blood 111 453 462 10.1182/blood-2007-06-094482 17967941 10.1182/blood-2007-06- 094482 1:CAS:528:DC%2BD1cXjtVKktQ%3D%3D
24. + cells J Exp Med 205 565 574 10.1084/jem.20071477 18283119 10.1084/jem.20071477 1:CAS:528: DC%2BD1cXjs1ahtbs%3D
25. + T regulatory cells Blood 109 2014 2022 10.1182/blood-2006-07-035279 17062729 10.1182/blood-2006-07-035279 1:CAS:528:DC%2BD2sXjtFeqtbk%3D
26. Y Zhang R Apilado J Coleman S Ben-Sasson S Tsang J Hu-Li WE Paul H Huang 2001 Interferon gamma stabilizes the T helper cell type 1 phenotype J Exp Med 194 165 172 11457891 10.1084/jem.194.2.165 1:CAS:528:DC%2BD3MXlsVCksbg%3D
27. Z Wang J Hong W Sun G Xu N Li X Chen A Liu L Xu B Sun JZ Zhang 2006 Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs J Clin Invest 116 2434 2441 10.1172/JCI25826 16906223 1:CAS:528: DC%2BD28Xps1SgsLc%3D
28. R de Vivar A Chavez ME de Vera X Liang MT Lotze 2009 The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma Med Oncol 26 Suppl 1 3 12 10.1007/s12032-008-9162-z
29. TR Malek AL Bayer 2004 Tolerance, not immunity, crucially depends on IL-2 Nat Rev Immunol 4 665 674 10.1038/nri1435 15343366 10.1038/nri1435 1:CAS:528:DC%2BD2cXntFCmt7c%3D
30. MA Burchill J Yang C Vogtenhuber BR Blazar MA Farrar 2007 IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells J Immunol 178 280 290 17182565 1:CAS:528:DC%2BD2sXnvVWj
31. Z Yao Y Kanno M Kerenyi G Stephens L Durant WT Watford A Laurence GW Robinson EM Shevach R Moriggl, et al. 2007 Nonredundant roles for Stat5a/b in directly regulating Foxp3 Blood 109 4368 4375 10.1182/blood-2006-11-055756 17227828 10.1182/blood-2006-11-055756 1:CAS:528:DC%2BD2sXls1amsL4%3D
32. + Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV J Clin Invest 119 551 564 10.1172/JCI36604 19229109 10.1172/JCI36604 1:CAS:528:DC%2BD1MXivF2ktL4%3D